Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese
Overview
Authors
Affiliations
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are well-known key immune checkpoints that play a crucial dampening effect on regulating T-cell homeostasis and self-tolerance. In this study, we aimed to evaluate the association between immune checkpoints (CTLA-4 and PD-1) and Posner-Schlossman syndrome (PSS) in a southern Chinese population. A total of 137 patients with PSS and 139 healthy controls from a southern Chinese population were recruited. Five single nucleotide polymorphisms (SNPs) of (rs733618, rs4553808, rs5742909, rs231775, and rs3087243) and five SNPs of (rs10204525, rs2227981, rs2227982, rs41386349, and rs36084323) were genotyped by SNaPshot technique. Soluble CTLA-4 (sCTLA-4) and soluble PD-1 (sPD-1) were determined by ELISA and antibody array assay, respectively. The frequencies of T allele at rs733618 and A allele at rs231775 of were significantly higher in PSS patients than in healthy controls (corrected ( ) = 0.037; = 0.044, respectively). The haplotype frequencies of CACGG haplotype (rs733618-rs4553808-rs5742909-rs231775-rs3087243) of and TGAGC haplotype (rs10204525-rs2227981-rs2227982-rs41386349-rs36084323) of in the PSS group was significantly lower than those in the control group ( = 0.015, = 0.034, respectively). Circulating plasma levels of sCTLA-4 and sPD-1 in PSS patients were significantly higher than those in controls (all < 0.001). The present study suggests that and genetic polymorphisms are associated with the susceptibility to PSS in a southern Chinese population. The upregulated circulating plasma protein levels of sCTLA-4 and sPD-1 might provide some hints regarding the dysfunction of immune checkpoints in PSS during the active status.
Jiao J, Gao F, Zhao H, Jiang M, Zhou Y, Liu D Int J Med Sci. 2025; 22(5):1109-1123.
PMID: 40027189 PMC: 11866526. DOI: 10.7150/ijms.107750.
Chu Y, Yu K, Lin W, Wang W, Chen D Biomedicines. 2023; 11(9).
PMID: 37760867 PMC: 10526089. DOI: 10.3390/biomedicines11092426.
Clinical Characteristics of Posner-Schlossman Syndrome Patients in China.
Gao T, Song S, Ke X, Li S, Zhang D, Chen X Biomed Res Int. 2023; 2023:4110344.
PMID: 36714029 PMC: 9883090. DOI: 10.1155/2023/4110344.
Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China.
Sheng Q, Sun Y, Zhai R, Fan X, Ying Y, Kong X Front Public Health. 2023; 10:1051378.
PMID: 36711335 PMC: 9880426. DOI: 10.3389/fpubh.2022.1051378.
Li J, Ji Y, Yang W, Yao Y, Wang S, Zhang Z Front Med (Lausanne). 2023; 9:1064449.
PMID: 36698797 PMC: 9868410. DOI: 10.3389/fmed.2022.1064449.